Impact of autologous stem cell transplantation on renal response in multiple myeloma patients with advanced renal failure

2019 ◽  
Vol 19 (10) ◽  
pp. e216-e217
Author(s):  
Chang Ki Min ◽  
Sung-Soo Park ◽  
Gi June Min ◽  
Silvia Park ◽  
Sung Eun Lee ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Renal Response ◽  
Advanced Renal Failure

scholarly journals PB2173 OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IMPACT OF RENAL FAILURE

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 975-976
Author(s):  
R. El Fatmi ◽  
R. Ouerghi ◽  
E. Azza ◽  
S. Riahi ◽  
D. Belloumi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation

scholarly journals PS1433 RESULTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 660-661
Author(s):  
A. Tülin Tuğlular ◽  
T. Elibol ◽  
C. Uzunoğlu ◽  
B. Aldağ ◽  
Ö. Dedeoğlu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation

scholarly journals Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?

2019 ◽  
Vol 2019 ◽  
pp. 1-12
Author(s):  
Hongfei Zhong ◽  
Xiaojie Xie ◽  
Gaosi Xu
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Renal Function ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Clinical Response ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Light Chain ◽  
Case Reports

Autologous stem cell transplantation (ASCT) is a standard treatment for multiple myeloma (MM), but the clinical response and renal curative effect in MM patients with renal failure (RF) remain controversial. The myeloma kidney disease has different types, and most are due to the direct toxic effects of light chain. Although ASCT can effectively clear the light chain, the data of renal function improvement are still limited. We reviewed the published literatures, focusing on the prospective studies, the retrospective analysis studies, and the case reports. RF patients who received ASCT displayed a low survival rate (OS: HR 1.95, 95% CI 1.020 to 3.720; I2=64.9%, P=0.014) and a shorter EFS/PFS (EFS/PFS: HR 1.53, 95% CI 1.090 to 2.140; I2=0%, P=0.669). However, ASCT was feasible and could have the similar clinical response outcomes compared with the normal renal function (CR: OR 1.013, 95% CI 0.569 to 1.804; I2=48.5%, P=0.101; PR: OR 1.013, 95% CI 0.342 to 1.226; I2=46.3%, P=0.144). Moreover, MM with RF after ASCT had a good improvement of renal function and melphalan is still an important factor affecting the treatment of ASCT.

MM-324: Efficacy of Autologous Stem Cell Transplantation in Multiple Myeloma Patients with Renal Failure

2021 ◽  
Vol 21 ◽  
pp. S435-S436
Author(s):  
Maya Firsova ◽  
Larisa Mendeleeva ◽  
Maxim Solovev ◽  
Hunan Julhakyan ◽  
Valeriy Savchenko
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation

Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4934-4934
Author(s):  
Patrizia Tosi ◽  
Elena Zamagni ◽  
Paola Tacchetti ◽  
Michela Ceccolini ◽  
Giulia Perrone ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Renal Function ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Creatinine Clearance ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
High Dose ◽  
Newly Diagnosed

Abstract Abstract 4934 Multiple myeloma (MM) patients presenting with renal feature at disease onset should not be excluded from high-dose therapy programs; seeking novel effective and non-nephrotoxic induction regimens is thus mandatory in order to maximize the reduction of tumor burden prior to transplant. From May 2002 to February 2008, 31 newly diagnosed MM patients (18 male, 13 female, median age 60 years) with symptomatic MM and renal failure, defined as creatinine clearance '50ml/min, were enrolled in a clinical trial aimed at evaluating the efficacy and the feasibility of a thalidomide-based regimen as induction therapy in preparation to autologous stem cell transplantation. Sixteen patients had a more severe renal impairment (creatinine clearance '30ml/min) and 7 of them were in chronic hemodyalisis. After informed consent, patients received four months of combined oral thalidomide (thal) (100mg/day for two weeks and 200mg/day thereafter) and dexamethasone (dex) (40mg/day on day 1-4, 9-11, 17-20/28 days on odd cycles and on day 1-4 on even cycles); peripheral blood stem cell collection was thus to be performed after priming with high-dose cyclophosphamide + G-CSF or G-CSF alone; a single or double autologous stem cell transplantation was then to follow, upon preparation with high-dose melphalan. After induction, a PR or better was obtained in 23 patients (74%), with 8 patients (26%) achieving a VGPR or better. No difference in response rate was observed in patients with a baseline creatinine clearance ≥30ml/min (86%) or < 30ml/min (62%). An improvement in renal function was more frequently observed in patients achieving ≥ PR (82% vs. 37% in patients obtaining < PR, p =0.04). Twenty-six patients underwent peripheral blood stem cell mobilization; in 17 of them (65%) the procedure was successful resulting in the collection of > 4 × 106 CD34+ cells/kg. Fifteen patients received a double autologous stem cell transplantation while a single transplant was performed in four patients. Overall, median event-free survival was 30 months, and median survival has not been reached, upon 32 months median follow-up. Toxicity profile of thal-dex was comparable to that observed in patients with a normal renal function. In conclusion, our data show that thal-dex can be safely administered in patients with newly diagnosed MM and renal failure. given the relationship between recovery of renal function and response to induction treatment, more intensive thal + bortezomib-including regimens could be potentially useful in order to rescue a higher number of patients. Disclosures Off Label Use: Thalidomide plus dexamethasone in newly diagnosed multiple myeloma.

scholarly journals MP331DOES RENAL FAILURE AFFECT OUTCOME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA?

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i449-i449
Author(s):  
Marlies Antlanger ◽  
Wolfgang W. Lamm ◽  
Edit Porpaczy ◽  
Thomas Reiter ◽  
Christoph Minichsdorfer ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation
Sign in / Sign up

Export Citation Format

Share Document